ASG Pharma (“ASG”), a subsidiary of Aphria Inc (OTCMKTS:APHQF), will be the first party to benefit from the first import license for medical cannabis that was recently issued out by the Malta Medicines Authority (“MMA”).
Obtaining the license and its associated benefits
One of the officials working with the company outlined that the license will enable ASG import medical cannabis for research and analytical testing. According to him, ASG is on its way to becoming the cornerstone in testing, research and development of medical cannabis across Europe despite the stiff competition being experienced at the moment.
The Head of International Development at Aphria Antonio Costanzo opined, “Malta’s legislative and regulatory standards are extremely rigorous, and we are pleased and proud that the MMA has awarded this import license to ASG. ASG adheres to the highest international standards and we look forward to upholding this high bar as a leading European hub for medical cannabis.”
An outlook into the future
The processing and manufacturing capabilities of ASG Pharma will soon be upgraded and that will be in an effort to increase its capability to process, extract, and package and label cannabis derivative pharmaceutical-grade medical and cannabis products.
The CEO of Aphria Vic Neufeld while addressing a number of news reporters said that their EU GMP-certified lab in Malta will present a gateway to medical cannabis markets across Europe and it is also worth mentioning that it is currently the top European center for R&D and testing.
He went a step further to outline that as a company they were pursuing the bets attractive strategic opportunities for medical cannabis not only in Europe but globally.
The passage of Bill C-45
The company through its spokesperson has outlined that it is indeed happy having witnessed the passage of Bill C-45 through the Senate. It is a new dawn for the company since it will now be able to provide safe and legal recreational cannabis in Canada.
And this is happening at a time when business dynamics tend to be shifting quite fast. It is easy to tell that the company is with the passage of time making progressive steps towards establishing itself as the preeminent leader in the global cannabis sector.
BevCanna A Leader In The North American Infused Beverage Sector
Why BevCanna May Already Have Pole Position for the Coming Cannabis Beverage Craze
New Opportunity: BevCanna Enterprises Inc. (CSE:BEV) (OTC:BVNNF)
- Leader/Innovator in Emerging multi-billion-dollar Cannabis-Infused Beverage space
- Recently announced coming transition to full commercial-stage operations in coming months
- Set to become Canada’s largest organic outdoor cannabis cultivator
- World-class bottling facility about to receive full cannabis-infused bev production license
- Launching in California and Canada with Sales ramping in Q3
The big Cannabis-infused product bull market of 2019 didn’t exactly pan out like so many had believed following the landmark US Farm Bill, momentum from regulatory authorities, and a spate of high-profile Fortune 500 JV moves (ie Molson Coors and HEXO, Altria and CRON, Constellation Brands and Canopy, etc) that seemed to suggest the writing was on the wall for this transformational trend to get in gear.
What happens when everyone gets excited about a big investment theme too early? That’s right! A destructive and painful bear market. This has been story for the whole cannabis space for the past year.
However, given a purging in the pot stock space and new regulatory measures now in place for cannabis-infused beverages in Canada and California, the explosive trend in cannabis beverages can now take flight.
We believe two points are key here for investors: 1. Cannabis-infused beverage leadership investments will be far superior to non-beverage plays in the cannabis sector because of the higher barrier to entry in terms of facilities, expertise, and regulatory hurdles, and 2. BevCanna Enterprises Inc. (OTCMKTS:BVNNF) (CSE:BEV) is likely to emerge as the big speculative winner this year in that niche given a number of inherent advantages and a proactive production ramping process that has already started to take hold.
As the cannabis space heals, BevCanna is supremely positioned to assume a leadership role in a space that is defined more by new adopters than by long-time cannabis consumers. Growth is being driven by new cannabis consumers exploring the marketplace given the expanded legality of cannabis. And new cannabis consumers are, on the margin, more likely to choose new ways of consuming cannabis – ie, many don’t want to smoke it.
According to Brightfield Group researchers, cannabis-infused beverages will represent one of the fastest growing segments of the overall cannabis product complex over the next 10 years. Fior Markets found that the global cannabis beverages market could generate $4.57 billion by 2025. Companies delivering cannabis drinks in Canada in 2020 will be set up for market dominance over the next 5-10 years as the trend takes flight.
BevCanna Enterprises Inc. (OTCMKTS:BVNNF) (CSE:BEV) shares are perfectly positioned to capitalize on this trend, which makes the company a likely candidate for some M&A chatter as cannabis-infused beverages expand to conquer the North American consumer this year.
BevCanna’s Inherent Advantages
BevCanna Enterprises Inc. (CSE:BEV, OTCMKTS:BVNNF) bills itself as an emerging leader in infused beverage manufacturing. The company develops and manufactures cannabinoid-infused beverages and consumer products for in-house brands and white label clients.
BVNNF has been in development-stage operations since IPO-ing last summer. According to recent company communications, the stage is set for a rapid transformation to full commercial-stage operations, with sales likely to hit full volume in Canadian and California markets starting in Q3 of this year.
The company runs a 40k sq ft HACCP certified manufacturing facility, with a current bottling capacity of up to 210M bottles per annum.
The facility is state-of-the-art, with the capability of producing custom bottle form factors and water-soluble cannabinoids. This opens up an immediately obvious leadership potential for white-label product development to complement the company’s in-house brands.
The company also has access to a 100+ acre outdoor cultivation site with an on-site natural spring aquifer.
The team is also a top-draw, with former leaders at Vega, Mike’s Hard Lemonade, and other top disruptive brands and companies in the functional beverage and wellness markets and highly-regulated markets, as well as veterans from Goldman Sachs, Frito Lay, and General Mills. So, they know how to commercialize into big market opportunities.
In other words, this is a company with a world-class facility and a world-class team. And they will be receiving their cannabis-infused beverage production license very soon (They already have the research and cultivation licenses).
There’s a high regulatory barrier to entry for the cannabis-infused beverage space. That will keep competition suppressed, leaving the big profits to be made those specialist players with the resources, equipment, expertise, and regulatory clearance to dominate this high-growth market niche.
BevCanna Enterprises Inc. (OTCMKTS:BVNNF) (CSE:BEV) may be the best of breed the publicly traded markets right now among companies that meet all of these criteria. More to the point, the company is on track to have some of the first cannabis-infused beverages on the market as this phase of the cannabis revolution just gets off the ground.
The Company recently announced that it is significantly expanding its manufacturing premises in anticipation of receiving its standard processing license and initiating full-scale commercialization this year.
In other words, they’re about to gain access to a massive and thriving market looking for cannabis-infused beverages. And the company wants to be ready to soak up every dime of potential sales right out of the gate. So these folks, being experienced business leaders, are getting ready to meet that demand with an increased capacity to produce product supplies when the bell rings and the government says “Go!”.
“This expansion is an exciting step for BevCanna,” said John Campbell, Chief Strategy Officer at BevCanna. “We expect to receive our standard processing license imminently, and we’re preparing to initiate full-scale production in the coming months. We’ve seen a fantastic consumer and industry response to the upcoming Canadian beverage market, and this development ensures that we have capacity and full product offerings to fulfil the anticipated demand.”
Just before that, the company announced that it has entered into a definitive joint venture agreement with Mota Ventures Corp. (CSE:MOTA FSE: 1WZ:GR OTC: PEMTF), to exclusively distribute BevCanna’s hemp-derived products in the European market.
That followed the company’s announcement that it is working with partner Nextleaf Solutions Ltd. (Nextleaf) (CSE:OILS, OTCQB:OILFF, FSE:L0MA), to employ their nano-delivery technology in BevCanna’s upcoming lines of cannabis-infused beverages. BevCanna will have the exclusive rights to commercialize this unique technology, giving the company yet another edge as a market leader in white label services.
According to the release, Nextleaf, BevCanna’s exclusive provider of water-soluble cannabinoids, has completed its acquisition of the intellectual property pertaining to the nano-delivery of cannabinoids. The acquisition includes the foundational processing methodology and two water-soluble formulations. Nextleaf intends to seek patent protection around the acquired IP and to partner with BevCanna to develop a new patent family around infused beverages.
“The IP allows consumers to feel the desired effect from cannabis-infused beverages in under 10 minutes,” said John Campbell, Chief Strategy Officer at BevCanna. “We’re eager to commercialize this innovative technology in Canada; and to act as the exclusive beverage commercialization partner, through BevCanna’s branded and white-label cannabis-infused beverages.”
Looking ahead, the company expects to receive its full license imminently, and then begin full commercial operations. In other words, this is the most exciting time to come across this stock: right in front of its most dramatic and market-moving catalysts, including full-licensing, initial product shipment, expanding sales, expanding markets, topline growth, and everything that analysts and investors typically scan for when hunting new speculative opportunities.
Right now, you have a chance at it ahead of that crowd.
One of the key points to make here is the stock’s relative strength. The cannabis equity sector has been destroyed over the past 6-12 months, and many are still in crash mode. At the same time, BVNNF shares show clear evidence of a major accumulation bid likely by smart money working to expand exposure ahead of the coming parade of high-profile catalysts just ahead for the stock.
Shares are sitting above major moving averages, but well-consolidated and ready for a potential next-leg higher if trendline resistance above the $0.33-0.35 area is cleared. This breakout would be very well supported given the nature of the stock’s basing process, which came on rising volume and bullish divergence on MACD.
About BevCanna Enterprises
BevCanna Enterprises Inc. (OTCMKTS:BVNNF) (CSE:BEV) develops and manufactures cannabinoid-infused beverages and consumer products for in-house brands and white label clients.
With decades of experience creating, branding and distributing iconic brands that have resonated with consumers on a global scale, the team demonstrates an expertise unmatched in the emerging cannabis beverage category.
Based in British Columbia, Canada, BevCanna has a 292-acre outdoor cultivation site in the Okanagan Valley and the exclusive rights to a pristine spring water aquifer, access to a world-class 40,000-square-foot, HACCP certified manufacturing facility, with a current bottling capacity of up to 210M bottles per annum.
BevCanna’s vision is to be a global leader in infused innovations.
- BevCanna Enterprises Inc. (OTCMKTS:BVNNF) (CSE:BEV) is about to receive its full cannabis-infused production license, which will allow the company to start ramping up full commercial operations as a likely leadership name in the Cannabis Bev space
- BevCanna Enterprises Inc. (OTCMKTS:BVNNF) (CSE:BEV) has a small trading float of just 38.3M, which suggests the stock could launch higher on any additional influx of interest.
- BevCanna Enterprises Inc. (OTCMKTS:BVNNF) (CSE:BEV) has a world-class facility and team, positioning the company as a dominant entity in the relatively closed loop of Canadian Cannabis-infused beverage producers
- BevCanna Enterprises Inc. (OTCMKTS:BVNNF) (CSE:BEV) has been demonstrating clear relative strength, outperforming peers in the cannabis space by a wide margin during the recent tailspin in the pot stock sector.
- BevCanna Enterprises Inc. (OTCMKTS:BVNNF) (CSE:BEV) just recorded a MACD Bullish divergence on a rising-volume base, suggesting a technical change in trend with upside breakout potential above.
- BevCanna Enterprises Inc. (OTCMKTS:BVNNF) (CSE:BEV) is set to start clocking big sales growth over coming months with innovative in-house branded products and a thriving white-label business targeting Canada and California
To circle back around, the cannabis bear market has come and possibly gone. And now it’s time to start picking through the rubble because there are probably some life-altering investment opportunities just lying around the floor right now in this space.
Our thesis remains: 1. Cannabis-infused beverages will offer more growth with less competition if you stick to best-of-breed plays, and 2. BevCanna, with its world-class state-of-the-art massive facility and blue-chip team with leadership experience in major markets across similar sectors, is about to gain its fully licensed access to that marketplace. And when that happens, BVNNF will be that best-of-breed name in the cannabis-infused beverage marketplace.
BetterLife Pharma Inc (OTCMKTS:PVOTF) Readies Interferon Alpha-2b To Clear Caronavirus From The Airways Of Patients
BetterLife Pharma Inc (OTCMKTS:PVOTF) expects to publish results of the third-party study of the drug – Interferon Alpha-2b in the journal Frontiers of Immunology this Friday. The company has examined the effectiveness of Interferon Alpha-2b on seventy-seven Wuhan based patients infected with moderate to severe coronavirus during January 16 and February 20, 2020. According to the study, the drug can effectively clear the coronavirus from the airways of affected patients.
An unexplored and uncontrolled study is conducted on seventy-seven patients in Wuhan by administering arbidol (200 mg t.i.d.) or nebulized IFN-α2b (5 mU b.i.d.) or a combination of both. In the trial, temperature, serum cytokine levels, blood chemistry, cell counts, and blood oxygen saturation levels are recorded. Interferon Alpha-2b has effectively reduced coronavirus duration either with or without arbidol in the upper respiratory tract. Further investigation is required on IFN-α2b to treat COVID-19.
Should give priority for clinical trials of Interferon Alpha-2b
The study is featured in the Canadian national newspaper – Globe and Mail in its May 13, edition under the article title ‘Interferon emerges as a potential treatment for COVID-19’. A researcher at Toronto University Health Network – Dr. Eleanor Fish said the awareness about this drug to treat coronavirus is slow and should give priority for the clinical trials on a large scale.
Interferons to treat coronavirus infections
According to Fish, interferons provide the first line of defense against all the viruses. However, viruses like coronavirus have evolved to block the response of interferon. It necessitates the need for interferons to treat coronavirus infections.
The new drug of BetterLife Pharma overrides the inhibitory effects of COVID-19. Fish said that instead of developing a virus-specific antiviral every time, it is better to consider interferons for the treatment of viruses like coronavirus.
Interferons have already received the nod to treat viral infections several years back. It is now time to repropose them to treat moderate to severe virus infections. Therefore, a large clinical trial involving Interferon Alpha-2b on a cohort of patients further supports the research.
CEO of BetterLife Pharma, Ahmad Doroudian, said the company is pleased with the results of a recently concluded study in using Interferon Alpha-2b to treat COVID-19. The outcome supports BetterLife’s approach to treating coronavirus. Ahmad said he supports the view of Fish and further excited by the recent study results.
CV Sciences Inc (OTCMKTS:CVSI) Navigates Market Storms
Any company that faces the campaign of short sellers experiences hard times; especially the shareholders. In the recent months, CV Sciences Inc (OTCMKTS:CVSI) had a rough battle with the investors which badly bruised the share price. In an Aug. 30, 2018 press statement, the company gave an update to shareholders regarding the situation.
In the update, CV Sciences acknowledges the “malicious” intent of the short sellers. The company CEO, Joseph Dowling further explains that they are victims of “campaigns run by short sellers in order to depress our stock price, so they could make financial windfalls.”
The CEO further details that: “We are also aware that at least one such group has boasted on social media platforms about its financial returns since their release of misleading information regarding the Company’s patent prosecution and drug development efforts.”
In rebuttal, the CEO affirms that the company presents strong financial numbers and that this will go on in future. He adds that there is nothing different with the business model since it is solid. Joseph speaks out so strongly about the “manipulations” and offers his sympathy for the shareholders.
“We will continue to do everything in our control to bring this activity to a halt. In the months ahead, we look forward to reporting our operating results in this fast-growing industry and providing updates on our drug development efforts,” he says.
A product milestone for CV Sciences Inc (OTCMKTS:CVSI)
The run in with the short sellers did not dampen the company’s spirits. In under two weeks, the company announced a great milestone for one of its products. The PlusCBD Oil
Such a status is important to product sales and consumer confidence in the company. Concurring with the assessment, the CEO says:
“We are committed to building consumer confidence and trust in the safety and quality of our products, supported by scientific evidence.